Abstract

A steep rise in Omicron reinfection cases suggests that this variant has increased immune evasion ability. To evaluate its antigenicity relationship with other variants, antisera from guinea pigs immunized with spike protein of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) were cross-tested against pseudotyped variants. The neutralization activity against Omicron was markedly reduced when other VOCs or VOIs were used as immunogens, and Omicron (BA.1)-elicited sera did not efficiently neutralize the other variants. However, a Beta or Omicron booster, when administered as the 4th dose 3-months after the 3rd dose of any of the variants, could elicit broad neutralizing antibodies against all of the current variants including Omicron BA.1. Further analysis with 280 available antigen–antibody structures and quantification of immune escape from 715 reported neutralizing antibodies provide explanations for the observed differential immunogenicity. Three distinct clades predicted using an in silico algorithm for clustering of sarbecoviruses based on immune escape provide key information for rational design of vaccines.

Details

Title
Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses
Author
Li, Qianqian 1 ; Zhang, Li 2 ; Liang, Ziteng 3 ; Wang, Nan 4   VIAFID ORCID Logo  ; Liu, Shuo 2 ; Li, Tao 2 ; Yu, Yuanling 2 ; Cui, Qianqian 2 ; Wu, Xi 2 ; Nie, Jianhui 2 ; Wu, Jiajing 2 ; Cui, Zhimin 2 ; Lu, Qiong 2 ; Wang, Xiangxi 4   VIAFID ORCID Logo  ; Huang, Weijin 2   VIAFID ORCID Logo  ; Wang, Youchun 3   VIAFID ORCID Logo 

 NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China (GRID:grid.440262.6); Jiangsu Recbio Technology Co., Ltd., Taizhou, China (GRID:grid.440262.6) 
 NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China (GRID:grid.440262.6) 
 NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China (GRID:grid.440262.6); Graduate School of Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839) 
 CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, CAS Key Laboratory of Infection and Immunity, Beijing, China (GRID:grid.418856.6) (ISNI:0000 0004 1792 5640) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2695305601
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.